AR087656A2 - Terapia combinada con inhibidores de cotransportador 2 de glucosa dependiente de sodio (sglt-2) y sus composiciones farmaceuticas - Google Patents
Terapia combinada con inhibidores de cotransportador 2 de glucosa dependiente de sodio (sglt-2) y sus composiciones farmaceuticasInfo
- Publication number
- AR087656A2 AR087656A2 ARP120103116A ARP120103116A AR087656A2 AR 087656 A2 AR087656 A2 AR 087656A2 AR P120103116 A ARP120103116 A AR P120103116A AR P120103116 A ARP120103116 A AR P120103116A AR 087656 A2 AR087656 A2 AR 087656A2
- Authority
- AR
- Argentina
- Prior art keywords
- benzene
- glucopyranos
- benzyl
- chloro
- yloxy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Reivindicación 1: Una composición farmacéutica caracterizada porque está compuesta por uno o más compuestos inhibidores de SGLT-2 combinados con uno o más segundos agentes terapéuticos, que es adecuada para el tratamiento de uno o más trastornos metabólicos, en la que i) dicho uno o más compuestos inhibidores de SGLT-2 comprenden un derivado de benceno sustituido con glucopiranosilo seleccionado del grupo de compuestos 1 - 17: (1) 1-cloro-2-(4-ciclopentiloxibencil)-4-(b-D-glucopiranos-1-il)-benceno; (2) 1-cloro-4-(b-D-glucopiranos-1-il)-2-[4-((R)-tetrahidrofuran-3-iloxi)-bencil]-benceno; (3) 1-cloro-4-(b-D-glucopiranos-1-il)-2-[4-((S)-tetrahidrofuran-3-iloxi)-bencil]-benceno; (4) 1-cloro-4-(b-D-glucopiranos-1-il)-2-[4-(tetrahidrofuran-2-on-3-iloxi)-bencil]-benceno; (5) 1-cloro-4-(b-D-glucopiranos-1-il)-2-(4-ciclobutiloxi-bencil)-benceno; (6) 1-cloro-4-(b-D-glucopiranos-1-il)-2-(4-ciclohexiloxi-bencil)-benceno; (7) 1-cloro-4-(b-D-glucopiranos-1-il)-2-[4-(tetrahidropiran-4-iloxi)-bencil]-benceno; (8) 1-cloro-4-(b-D-glucopiranos-1-il)-2-[4-(1-acetil-piperidin-4-iloxi)-bencil]-benceno; (10) 1-(b-D-glucopiranos-1-il)-4-metil-3-[4-(tetrahidrofuran-3-iloxi)-bencil]-benceno; (11) 1-(b-D-glucopiranos-1-il)-4-metil-3-[4-(2-trimetilsilil-etil)-bencil]-benceno; (12) 1-cloro-4-(b-D-glucopiranos-1-il)-2-(4-etinilbencil)benceno; (13) 1-cloro-4-(b-D-glucopiranos-1-il)-2-[4-(piperidin-4-iloxi)-bencil]-benceno; (14) 1-fluoro-4-(b-D-glucopiranos-1-il)-2-(4-etinilbencil)benceno; (15) 1-(b-D-glucopiranos-1-il)-3-(4-etinil-bencil)-benceno; (16) 1-etinil-4-(b-D-glucopiranos-1-il)-2-(4-etoxi-bencil)-benceno; y (17) 1-metoxi-4-(b-D-glucopiranos-1-il)-2-(4-etinil-bencil)-benceno; o uno de sus tautómeros, sus estereoisómeros, las mezclas de los mismos o sus sales; o uno de sus profármacos, en los que uno o más grupos hidroxilo del grupo b-D-glucopiranosilo están acilados con grupos seleccionados de (alquil C₁₋₃)carbonilo, (alquil C₁₋₆)oxicarbonilo, fenilcarbonilo, fenil-(alquil C₁₋₃)-carbonilo, feniloxicarbonilo, y fenil-(alquil C₁₋₃)-oxicarbonilo, o una de sus sales farmacéuticamente aceptable; y ii) dichos uno o más segundos agentes terapéuticos que son adecuados para el tratamiento de uno o más trastornos metabólicos comprenden: a) una biguanida, b) una sulfonilurea (SU), c) una tiazolidindiona (agonista de PPARg), d) un bloqueador de a-glucosidasa, e) insulina o un análogo de insulina, f) GLP1 o un análogo de GLP1, g) un modulador de PPARg, h) un modulador de PPARg/a, i) un agonista del polipéptido insulinotrópico dependiente de glucosa, j) un agonista b-3, o k) un activador de glucoquinasa. Reivindicación 8: La composición farmacéutica según una cualquiera de las reivindicaciones 1 a 7, caracterizada porque dicho segundo agente terapéutico es metformina, glimepirida, una tiazolidindiona o miglitol.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US86509906P | 2006-11-09 | 2006-11-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR087656A2 true AR087656A2 (es) | 2014-04-09 |
Family
ID=39078598
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP070104986A AR063627A1 (es) | 2006-11-09 | 2007-11-08 | Terapia combinada con inhibidores de sgl t-2 y sus composiciones farmaceuticas |
ARP120103116A AR087656A2 (es) | 2006-11-09 | 2012-08-23 | Terapia combinada con inhibidores de cotransportador 2 de glucosa dependiente de sodio (sglt-2) y sus composiciones farmaceuticas |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP070104986A AR063627A1 (es) | 2006-11-09 | 2007-11-08 | Terapia combinada con inhibidores de sgl t-2 y sus composiciones farmaceuticas |
Country Status (23)
Country | Link |
---|---|
US (3) | US20100298243A1 (es) |
EP (2) | EP3037095A3 (es) |
JP (1) | JP5337040B2 (es) |
KR (1) | KR101463724B1 (es) |
CN (1) | CN101534815A (es) |
AR (2) | AR063627A1 (es) |
AU (1) | AU2007316613B2 (es) |
BR (1) | BRPI0718596B8 (es) |
CA (2) | CA3007700A1 (es) |
CL (1) | CL2007003227A1 (es) |
CO (1) | CO6190509A2 (es) |
EA (1) | EA018495B1 (es) |
IL (1) | IL198591A0 (es) |
MA (1) | MA30875B1 (es) |
MX (1) | MX2009004104A (es) |
MY (1) | MY157828A (es) |
NO (1) | NO20091229L (es) |
NZ (1) | NZ598778A (es) |
TN (1) | TN2009000177A1 (es) |
TW (1) | TWI448291B (es) |
UA (1) | UA100008C2 (es) |
WO (1) | WO2008055940A2 (es) |
ZA (1) | ZA200902084B (es) |
Families Citing this family (110)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE457169T1 (de) | 1998-10-15 | 2010-02-15 | Imp Innovations Ltd | Verbindungen für die behandlung von gewichtsverlust |
US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
CN103435581B (zh) * | 2004-03-16 | 2015-08-19 | 贝林格尔.英格海姆国际有限公司 | 吡喃葡萄糖基取代的苯基衍生物、含该化合物的药物、其用途及其制造方法 |
DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
UA91546C2 (uk) * | 2005-05-03 | 2010-08-10 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ |
US7772191B2 (en) | 2005-05-10 | 2010-08-10 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein |
DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
RU2008113050A (ru) * | 2005-09-08 | 2009-10-20 | БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) | КРИСТАЛЛИЧЕСКИЕ ФОРМЫ 1-ХЛОР-4-(β-D-ГЛЮКОПИРАНОЗ-1-ИЛ)-2-(4-ЭТИНИЛБЕНЗИН)-БЕНЗОЛА, СПОСОБ ЕГО ПОЛУЧЕНИЯ И ЕГО ПРИМЕНЕНИЕ ДЛЯ ПРИГОТОВЛЕНИЯ ЛЕКАРСТВЕННЫХ СРЕДСТВ |
PE20080697A1 (es) * | 2006-05-03 | 2008-08-05 | Boehringer Ingelheim Int | Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion |
EA030606B1 (ru) | 2006-05-04 | 2018-08-31 | Бёрингер Ингельхайм Интернациональ Гмбх | Способы приготовления лекарственного средства, содержащего полиморфы |
PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
US8039441B2 (en) * | 2006-08-15 | 2011-10-18 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as SGLT inhibitors and process for their manufacture |
US8283326B2 (en) * | 2006-10-27 | 2012-10-09 | Boehringer Ingelheim International Gmbh | Crystalline form of 4-(beta-D-glucopyranos-1-yl)-1-methyl-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
GB0624282D0 (en) | 2006-12-05 | 2007-01-10 | Cavalla David | Treatment of cachexia |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
PE20090938A1 (es) | 2007-08-16 | 2009-08-08 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo |
WO2009035969A1 (en) | 2007-09-10 | 2009-03-19 | Janssen Pharmaceutica N.V. | Process for the preparation of compounds useful as inhibitors of sglt |
US8648085B2 (en) | 2007-11-30 | 2014-02-11 | Boehringer Ingelheim International Gmbh | 1, 5-dihydro-pyrazolo (3, 4-D) pyrimidin-4-one derivatives and their use as PDE9A mudulators for the treatment of CNS disorders |
UA105362C2 (en) | 2008-04-02 | 2014-05-12 | Бьорингер Ингельхайм Интернациональ Гмбх | 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators |
PE20091730A1 (es) | 2008-04-03 | 2009-12-10 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
CN102105153B (zh) * | 2008-05-22 | 2014-03-05 | 百时美施贵宝公司 | Sglt2抑制剂的医药用途和含该抑制剂的组合物 |
KR20200118243A (ko) | 2008-08-06 | 2020-10-14 | 베링거 인겔하임 인터내셔날 게엠베하 | 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료 |
UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
AP2011005672A0 (en) | 2008-09-08 | 2011-04-30 | Boehringer Ingelheim Int | Pyrazolopyrimidines and their use for the treatment of CNS disorders. |
KR20110067096A (ko) | 2008-09-10 | 2011-06-21 | 베링거 인겔하임 인터내셔날 게엠베하 | 당뇨병 및 관련 상태를 치료하기 위한 병용 요법 |
US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
US9056850B2 (en) | 2008-10-17 | 2015-06-16 | Janssen Pharmaceutica N.V. | Process for the preparation of compounds useful as inhibitors of SGLT |
JP2012512848A (ja) | 2008-12-23 | 2012-06-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 有機化合物の塩の形態 |
AR074990A1 (es) | 2009-01-07 | 2011-03-02 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina |
UY32427A (es) | 2009-02-13 | 2010-09-30 | Boheringer Ingelheim Internat Gmbh | Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma |
CN102387783A (zh) | 2009-02-13 | 2012-03-21 | 贝林格尔.英格海姆国际有限公司 | 包含吡喃葡萄糖基二苯基甲烷衍生物的药物组合物、其药物剂型、其制备方法及其在患者中改善血糖控制的用途 |
WO2010092125A1 (en) * | 2009-02-13 | 2010-08-19 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition comprising a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof |
SG173587A1 (en) | 2009-02-13 | 2011-09-29 | Boehringer Ingelheim Int | Sglt-2 inhibitor for treating type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance or hyperglycemia |
NZ594567A (en) | 2009-03-31 | 2013-12-20 | Boehringer Ingelheim Int | 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators |
KR20150046382A (ko) * | 2009-04-16 | 2015-04-29 | 다이쇼 세이야꾸 가부시끼가이샤 | 제약 조성물 |
US8541380B2 (en) | 2009-06-19 | 2013-09-24 | Green Cross Corporation | C-aryl glucoside SGLT2 inhibitors and pharmaceutical compositions comprising same |
US20110009347A1 (en) * | 2009-07-08 | 2011-01-13 | Yin Liang | Combination therapy for the treatment of diabetes |
EP2451797B1 (en) | 2009-07-10 | 2013-04-03 | Janssen Pharmaceutica, N.V. | CRYSTALLISATION PROCESS FOR 1-(ß-D-GLUCOPYRANOSYL)-4-METHYL-3-[5-(4-FLUOROPHENYL)-2-THIENYLMETHYL]BENZENE |
EP2483286B1 (en) | 2009-09-30 | 2016-07-13 | Boehringer Ingelheim International GmbH | Method for the preparation of a crystalline form of 1-chloro-4-(beta-d-glucopyranos-1-yl)-2-(4-((s)-tetrahydrofuran-3-yloxy)benzyl)benzene |
PT2486029E (pt) * | 2009-09-30 | 2015-10-14 | Boehringer Ingelheim Int | Processos para a preparação de derivados de benzil-benzeno substituídos com glucopiranosilo |
UY32919A (es) | 2009-10-02 | 2011-04-29 | Boehringer Ingelheim Int | Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos |
WO2011047113A1 (en) | 2009-10-14 | 2011-04-21 | Janssen Pharmaceutica Nv | Process for the preparation of compounds useful as inhibitors of sglt2 |
ME02016B (me) | 2009-11-02 | 2015-05-20 | Pfizer | Derivati dioksabiciklo[3.2.1]oktan-2,3,4-triola |
RS57926B1 (sr) | 2009-11-13 | 2019-01-31 | Astrazeneca Ab | Formulacije tablete sa trenutnim oslobađanjem |
BR112012012641A2 (pt) | 2009-11-27 | 2020-08-11 | Boehringer Ingelheim International Gmbh | TRATAMENTO DE PACIENTES DIABÉTICOS GENOTIPADOS COM INIBIDORES DE DPP-lVTAL COMO LINAGLIPTINA |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2011120923A1 (en) | 2010-03-30 | 2011-10-06 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition comprising an sglt2 inhibitor and a ppar- gamma agonist and uses thereof |
WO2011138421A1 (en) | 2010-05-05 | 2011-11-10 | Boehringer Ingelheim International Gmbh | Combination therapy |
CN108354930A (zh) | 2010-05-11 | 2018-08-03 | 詹森药业有限公司 | 包含1-(β-D-吡喃葡萄糖基)-2-噻吩基-甲基苯衍生物的药物制剂 |
WO2011157827A1 (de) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
EP3366304B1 (en) | 2010-06-24 | 2020-05-13 | Boehringer Ingelheim International GmbH | Diabetes therapy |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
WO2012020022A1 (en) | 2010-08-12 | 2012-02-16 | Boehringer Ingelheim International Gmbh | 6-cycloalkyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a inhibitors |
WO2012025857A1 (en) | 2010-08-23 | 2012-03-01 | Hetero Research Foundation | Cycloalkyl methoxybenzyl phenyl pyran derivatives as sodium dependent glucose co transporter (sglt2) inhibitors |
WO2012041898A1 (en) | 2010-09-29 | 2012-04-05 | Celon Pharma Sp. Z O.O. | Combination of sglt2 inhibitor and a sugar compound for the treatment of diabetes |
US20120283169A1 (en) * | 2010-11-08 | 2012-11-08 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
US20130035281A1 (en) | 2011-02-09 | 2013-02-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US8809345B2 (en) | 2011-02-15 | 2014-08-19 | Boehringer Ingelheim International Gmbh | 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders |
AR085689A1 (es) * | 2011-03-07 | 2013-10-23 | Boehringer Ingelheim Int | Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2 |
HUE030116T2 (en) | 2011-04-13 | 2017-04-28 | Janssen Pharmaceutica Nv | A method for preparing compounds useful as inhibitors of SGLT2 |
TWI542596B (zh) | 2011-05-09 | 2016-07-21 | 健生藥品公司 | (2s,3r,4r,5s,6r)-2-(3-((5-(4-氟苯基)噻吩-2-基)甲基)-4-甲基苯基)-6-(羥甲基)四氫-2h-哌喃-3,4,5-三醇之l-脯胺酸及檸檬酸共晶體 |
BR112013031032A2 (pt) * | 2011-06-03 | 2016-11-29 | Boehringer Ingelheim Int | inibidores de sglt-2 para o tratamento de distúrbios metabólicos em pacientes tratados com agentes neurolépticos |
US20130035298A1 (en) | 2011-07-08 | 2013-02-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
CN102863417B (zh) * | 2011-07-09 | 2015-01-14 | 山东轩竹医药科技有限公司 | C-糖苷衍生物 |
WO2013010964A1 (en) | 2011-07-15 | 2013-01-24 | Boehringer Ingelheim International Gmbh | Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
US9555001B2 (en) * | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
US9192617B2 (en) * | 2012-03-20 | 2015-11-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
WO2013171167A1 (en) | 2012-05-14 | 2013-11-21 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome |
WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
ES2959444T3 (es) | 2013-04-04 | 2024-02-26 | Boehringer Ingelheim Vetmedica Gmbh | Tratamiento de trastornos metabólicos en animales equinos |
US20140303097A1 (en) | 2013-04-05 | 2014-10-09 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
CA2812519A1 (en) * | 2013-04-05 | 2014-10-05 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
ES2702174T3 (es) | 2013-04-05 | 2019-02-27 | Boehringer Ingelheim Int | Usos terapéuticos de empagliflozina |
US11813275B2 (en) | 2013-04-05 | 2023-11-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
EA033286B1 (ru) | 2013-04-18 | 2019-09-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Способ лечения или отсрочки развития хронической болезни почек |
EP4285995A3 (en) | 2013-12-17 | 2024-02-28 | Boehringer Ingelheim Vetmedica GmbH | An sglt-2 inhibitor for use in the treatment of a metabolic disorder in feline animals |
US9902751B2 (en) | 2013-12-30 | 2018-02-27 | Mylan Laboratories Limited | Process for the preparation of empagliflozin |
KR20220097538A (ko) | 2014-01-23 | 2022-07-07 | 베링거잉겔하임베트메디카게엠베하 | 개과 동물에서 대사 장애의 치료 |
ES2950384T3 (es) | 2014-02-28 | 2023-10-09 | Boehringer Ingelheim Int | Uso médico de un inhibidor de DPP-4 |
NZ723781A (en) | 2014-04-01 | 2022-09-30 | Boehringer Ingelheim Vetmedica Gmbh | Treatment of metabolic disorders in equine animals |
US20170319539A1 (en) * | 2014-10-01 | 2017-11-09 | Mylan Laboratories Ltd. | Amorphous Empagliflozin |
CA2979033A1 (en) | 2015-03-09 | 2016-09-15 | Intekrin Therapeutics, Inc. | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy |
US20170071970A1 (en) | 2015-09-15 | 2017-03-16 | Janssen Pharmaceutica Nv | Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders |
JP2018530592A (ja) | 2015-10-15 | 2018-10-18 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 代謝性ミオパチーの治療に使用するためのsglt−2阻害剤 |
EP3468562A1 (en) | 2016-06-10 | 2019-04-17 | Boehringer Ingelheim International GmbH | Combinations of linagliptin and metformin |
US11253508B2 (en) | 2017-04-03 | 2022-02-22 | Coherus Biosciences, Inc. | PPARy agonist for treatment of progressive supranuclear palsy |
KR102204439B1 (ko) | 2018-05-14 | 2021-01-18 | 에이치케이이노엔 주식회사 | Sglt-2 억제제 및 dpp-iv 억제제를 포함하는 약제학적 조성물 |
WO2019228366A1 (zh) | 2018-05-31 | 2019-12-05 | 华领医药技术(上海)有限公司 | 含葡萄糖激酶激活剂和α-葡萄糖苷酶抑制剂的药物组合、组合物和制剂及其制备方法和用途 |
WO2020039394A1 (en) | 2018-08-24 | 2020-02-27 | Novartis Ag | New drug combinations |
CN110141555A (zh) * | 2019-06-21 | 2019-08-20 | 江苏豪森药业集团有限公司 | 一种恩格列净片及其制备方法 |
BR112022001314A2 (pt) * | 2019-07-26 | 2022-03-22 | Dongbao Purple Star Hangzhou Biopharmaceutical Co Ltd | Inibidor de sglts/dpp4 e aplicação do mesmo |
US11759474B2 (en) | 2019-11-28 | 2023-09-19 | Boehringer Ingelheim Vetmedica Gmbh | Use of SGLT-2 inhibitors in the drying-off of non-human mammals |
AU2021222297A1 (en) | 2020-02-17 | 2022-08-04 | Boehringer Ingelheim Vetmedica Gmbh | Use of SGLT-2 inhibitors for the prevention and/or treatment of cardiac diseases in felines |
KR20220151634A (ko) | 2020-03-06 | 2022-11-15 | 버텍스 파마슈티칼스 인코포레이티드 | Apol-1 의존성 국소 분절성 사구체경화증을 치료하는 방법 |
WO2022051316A1 (en) | 2020-09-03 | 2022-03-10 | Coherus Biosciences, Inc. | Fixed dose combinations of chs-131 and a sglt-2 inhibitor |
CN112206216B (zh) * | 2020-10-15 | 2023-03-17 | 江西华士药业有限公司 | 一种缓释达格列净的制备方法 |
KR20230001000A (ko) | 2021-06-25 | 2023-01-03 | (주)휴온스 | 약물방출 특성이 개선된 엠파글리플로진 및 메트포르민 복합제제 |
WO2023006718A1 (en) | 2021-07-28 | 2023-02-02 | Boehringer Ingelheim Vetmedica Gmbh | Use of sglt-2 inhibitors for the prevention and/or treatment of cardiac diseases in non-human mammals excluding felines, in particular canines |
EP4376819A1 (en) | 2021-07-28 | 2024-06-05 | Boehringer Ingelheim Vetmedica GmbH | Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals |
CA3224673A1 (en) | 2021-07-28 | 2023-02-02 | Boehringer Ingelheim Vetmedica Gmbh | Use of sglt-2 inhibitors for the prevention and/or treatment of renal diseases in non-human mammals |
US20230381101A1 (en) | 2022-05-25 | 2023-11-30 | Boehringer Ingelheim Vetmedica Gmbh | Aqueous pharmaceutical compositions comprising sglt-2 inhibitors |
KR102490653B1 (ko) * | 2022-08-03 | 2023-01-20 | 진양제약주식회사 | 다파글리플로진 및 글리메피리드를 포함하는 약제학적 조성물 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6498193B2 (en) * | 1999-12-22 | 2002-12-24 | Trustees Of Dartmouth College | Treatment for complications of type 2 diabetes |
US7276624B2 (en) * | 2002-05-14 | 2007-10-02 | E. I. Du Pont De Nemours And Company | Fluorosulfates of hexafluoroisobutylene and its higher homologs |
CN103435581B (zh) | 2004-03-16 | 2015-08-19 | 贝林格尔.英格海姆国际有限公司 | 吡喃葡萄糖基取代的苯基衍生物、含该化合物的药物、其用途及其制造方法 |
US20080139484A1 (en) * | 2004-09-29 | 2008-06-12 | Kissei Pharmaceutical Co., Ltd. | 1(Beta-D-Glycopyranosyl)-3-Substituted Nitrogenous Heterocyclic Compound, Medicinal Composition Containing the Same, and Medicinal Use Thereof |
DE102004048388A1 (de) * | 2004-10-01 | 2006-04-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | D-Pyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
-
2007
- 2007-11-08 NZ NZ598778A patent/NZ598778A/xx unknown
- 2007-11-08 KR KR1020097011948A patent/KR101463724B1/ko active IP Right Review Request
- 2007-11-08 EP EP16152228.9A patent/EP3037095A3/en not_active Ceased
- 2007-11-08 EA EA200900626A patent/EA018495B1/ru active Protection Beyond IP Right Term
- 2007-11-08 WO PCT/EP2007/062023 patent/WO2008055940A2/en active Application Filing
- 2007-11-08 CN CNA2007800418788A patent/CN101534815A/zh active Pending
- 2007-11-08 JP JP2009535727A patent/JP5337040B2/ja active Active
- 2007-11-08 EP EP07822331A patent/EP2081569A2/en not_active Ceased
- 2007-11-08 AU AU2007316613A patent/AU2007316613B2/en active Active
- 2007-11-08 UA UAA200905233A patent/UA100008C2/ru unknown
- 2007-11-08 TW TW096142254A patent/TWI448291B/zh active
- 2007-11-08 CA CA3007700A patent/CA3007700A1/en not_active Withdrawn
- 2007-11-08 US US12/513,763 patent/US20100298243A1/en not_active Abandoned
- 2007-11-08 MX MX2009004104A patent/MX2009004104A/es active IP Right Grant
- 2007-11-08 CA CA002669043A patent/CA2669043A1/en not_active Withdrawn
- 2007-11-08 MY MYPI20091861A patent/MY157828A/en unknown
- 2007-11-08 AR ARP070104986A patent/AR063627A1/es not_active Application Discontinuation
- 2007-11-08 CL CL200703227A patent/CL2007003227A1/es unknown
- 2007-11-08 BR BRPI0718596A patent/BRPI0718596B8/pt active IP Right Grant
-
2009
- 2009-03-25 ZA ZA200902084A patent/ZA200902084B/xx unknown
- 2009-03-25 NO NO20091229A patent/NO20091229L/no not_active Application Discontinuation
- 2009-05-06 IL IL198591A patent/IL198591A0/en unknown
- 2009-05-07 CO CO09046030A patent/CO6190509A2/es not_active Application Discontinuation
- 2009-05-08 TN TNP2009000177A patent/TN2009000177A1/fr unknown
- 2009-05-08 MA MA31853A patent/MA30875B1/fr unknown
-
2012
- 2012-08-23 AR ARP120103116A patent/AR087656A2/es not_active Application Discontinuation
-
2015
- 2015-10-13 US US14/881,465 patent/US20160030385A1/en not_active Abandoned
-
2017
- 2017-03-22 US US15/465,680 patent/US20170189437A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR087656A2 (es) | Terapia combinada con inhibidores de cotransportador 2 de glucosa dependiente de sodio (sglt-2) y sus composiciones farmaceuticas | |
CL2011001735A1 (es) | Composicion farmaceutica que comprende: a) el inhibidor de sglt2 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)-bencil]-benceno, b) el inhibidor de dppiv linagliptina y c) un tercer agente antidiabetico que es clorhidrato de metformina; y su uso para tratar la diabetes mellitus tipo 2. | |
Schaefer | Small leucine-rich proteoglycans in kidney disease | |
ES2557303T3 (es) | Agente terapéutico para la estenosis del canal espinal | |
AR056055A1 (es) | Complejos cristalinos e hidratos de 1-cloro-4-(beta-d-glucopiranos-1-il)-2-(4-etinil-bencil)-benceno | |
AR064969A1 (es) | Composicion farmaceutica que comprende un derivado de pirazol -o- glucosido | |
CL2012000793A1 (es) | Composicion farmaceutica que comprende 1-cloro-4-(3-d-glucopiranos-il)-2-[4-((s)-tetrahidrofuran-3-iloxi)-bencil]benceno, clorhidrato de metformina y uno o mas excipientes farmaceuticos. | |
AR075424A1 (es) | Composicion farmaceutica que comprende un inhibidor de sglt2, metodos de tratamiento y sus usos | |
AR058901A1 (es) | Compuestos derivados de hidantoina, utiles para el tratamiento de trastornos inflamatorios y composicion farmaceutica que los comprende | |
AR082068A2 (es) | Analogos de nucleosidos fluorados modificados | |
ECSP066855A (es) | Derivados de benceno sustituidos por glucopiranosilo, medicamentos que contienen esos compuestos, su aplicación y procedimiento para su preparación | |
AR055070A1 (es) | Una composicion farmaceutica de liberacion sostenida, proceso para la preparacion de dicha composicion, metodo para la utilizacion de la misma y su uso | |
JP2017515908A5 (es) | ||
AR080444A1 (es) | Metodos para la utilizacion de cotransportadores de sodio-glucosa 1 y 2 | |
AR067271A1 (es) | Derivados de triazolona inhibidores no nucleosidos de la transcriptasa inversa, utiles para el tratamiento de enfermedades mediadas por el vih o el arc y composiciones farmaceuticas que los contienen. | |
RU2009140298A (ru) | Бензиловые производные гликозидов и способы их применения | |
CL2009001059A1 (es) | Compuestos derivados de 1,3-oxazin-2-ona-3,6 sustituidos, inhibidores de la actividad de la 11-beta-hidroxiesteroide deshidrogenasa i; composicion farmaceutica que los comprende; utiles en el tratamiento de enfermedades tales como diabetes mellitus, entre otras. | |
AR096811A1 (es) | Composiciones sinérgicas, proceso para prepararlas, compuesto, uso del mismo y método de tratamiento | |
BRPI0509074A (pt) | composições farmacêuticas compreendendo agonistas do receptor da tiróide | |
ECSP13012704A (es) | Moduladores del receptor gpr119 y el tratamiento de trastornos relacionados con este | |
ECSP099427A (es) | Barra de Tierra Segunda Generación 16 conexiones | |
AR035611A1 (es) | 2 -azetidinonas sustituidas con azucares, composicion farmaceutica, un kit, uso de dichos compuestos para la fabricacion de medicamentos utiles como agentes hipocolesterolemicos. | |
CO6511222A2 (es) | Derivado de idenona y composición famacéutica que comprende el mismo | |
CL2008001469A1 (es) | Uso de compuestos derivado de 3,5-bitenil-1,2,4-triazol para el tratamiento de la formacion de biopeliculas de p.aeruginosa en un paciente con fibrosis quistica; y combinacion farmaceutica que comprende un compuesto de formula i y un antibiotico seleccionado de gentamicina,amicacina, tobramicina, ciprofloxacino, entre otros. | |
ES2532084T3 (es) | Composiciones de topiramato y métodos para su uso |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |